CNBX Pharmaceuticals Inc. (CNBX) Return on Assets (2013 - 2026)
CNBX Pharmaceuticals' (CNBX) quarterly Return on Assets came in at 2.87% in Q2 2026, down 281.0% YoY from 1.59% in Q2 2025, and up 3.27% on a QoQ basis from 2.97% in Q1 2026.
CNBX Pharmaceuticals Inc. (CNBX) Return on Assets (2013 - 2026) Analysis & Trends
CNBX Pharmaceuticals (CNBX) has 14 years of Return on Assets data on file, last reported at 2.87% in Q2 2026.
- Quarterly Return on Assets fell 281.0% year-over-year to 2.87% in Q2 2026, while the trailing twelve-month figure through May 2026 was 2.87% (down 281.0% YoY) and the FY2025 annual result came in at 1.53%, down 138.0% from the prior year.
- Return on Assets grew to 2.87% in Q2 2026, from 2.97% in the prior quarter.
- In the past five years, Return on Assets ranged from a high of 0.02% in Q3 2023 to a low of 2.97% in Q1 2026.
- A 5-year average of 0.63% and a median of 0.05% in 2022 frame the typical range for Return on Assets.
- Annual changes were most pronounced in 2023 — Return on Assets gained 2 bps — and 2026, when it slumped 288 bps.
- Tracing CNBX's Return on Assets over 5 years: stood at 0.04% in 2022, then soared by 56 bps to 0.02% in 2023, then tumbled by 900 bps to 0.17% in 2024, then sank by 1429 bps to 2.64% in 2025, then slipped by 9 bps to 2.87% in 2026.
- The last three Return on Assets figures came in at 2.87% (Q2 2026), 2.97% (Q1 2026), and 2.64% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -2.87% |
| Feb 28, 2026 | -2.97% |
| Nov 30, 2025 | -2.64% |
| Aug 31, 2025 | -2.07% |
| May 31, 2025 | -0.06% |
| Feb 28, 2025 | -0.09% |
| Nov 30, 2024 | -0.17% |
| Aug 31, 2024 | -0.11% |
| May 31, 2024 | -0.06% |
| Feb 29, 2024 | -0.03% |
| Nov 30, 2023 | -0.02% |
| Aug 31, 2023 | -0.02% |
| May 31, 2023 | -0.02% |
| Feb 28, 2023 | -0.03% |
| Nov 30, 2022 | -0.04% |
| Aug 31, 2022 | -0.04% |
| May 31, 2022 | -0.04% |
| Feb 28, 2022 | -0.03% |
| Nov 30, 2021 | -0.01% |
| Aug 31, 2021 | -0.01% |